Motpoly Xr

Lacosamide is a functionalized amino acid anticonvulsant used to treat focal-onset and primary generalized tonic-clonic seizures. It works by selectively enhancing the slow inactivation of voltage-gated sodium channels to stabilize neuronal membranes.

For adults (17 years and older) with focal-onset seizures, the standard dosing regimen typically begins with a low dose to minimize side effects, followed by a gradual titration.

• Initial Monotherapy: Healthcare providers often start with 100 mg twice daily (200 mg/day). Depending on the patient's response and tolerability, the dose may be increased at weekly intervals by 50 mg twice daily. The recommended maintenance dose for monotherapy is usually 150 mg to 200 mg twice daily (300 mg to 400 mg per day).
• Adjunctive Therapy: The starting dose is usually 50 mg twice daily (100 mg/day). The dose is then increased weekly by 50 mg twice daily until the target maintenance dose of 100 mg to 200 mg twice daily is reached.
• Loading Dose: In some clinical scenarios, a single loading dose of 200 mg may be administered, followed approximately 12 hours later by the start of a maintenance regimen. Loading doses should be administered under medical supervision due to the increased risk of acute CNS side effects.

Lacosamide is approved for pediatric patients as young as 1 month old. Dosing in children is strictly weight-based:

• For children weighing 50 kg or more: The adult dosing schedule is generally followed.
• For children weighing less than 50 kg: Dosing is calculated in milligrams per kilogram (mg/kg). For example, a common starting dose for focal-onset seizures is 1 mg/kg twice daily, titrated up to a maintenance range of 3 mg/kg to 6 mg/kg twice daily, depending on age and weight bracket.

Renal Impairment

In patients with mild to moderate renal impairment, no dose adjustment is typically required. However, for those with severe renal impairment (Creatinine Clearance < 30 mL/min) or end-stage renal disease, the maximum recommended dose is 300 mg per day. For patients on hemodialysis, a supplemental dose of up to 50% of the daily dose may be considered following the dialysis session.

Hepatic Impairment

Patients with mild to moderate hepatic impairment should be monitored closely during titration. The maximum recommended dose for these patients is 300 mg per day. Lacosamide is not recommended for patients with severe hepatic impairment as its safety and efficacy have not been established in this population.

Elderly Patients

While no specific dose adjustment is mandated based solely on age, elderly patients often have reduced renal function. Clinicians typically start at the lower end of the dosing range and titrate more slowly to monitor for dizziness or balance issues.

• Consistency: Take Lacosamide at the same times every day (e.g., 8:00 AM and 8:00 PM) to maintain a steady level in your blood.
• Administration: Tablets should be swallowed whole with a glass of water. They can be taken with or without food. Do not crush or chew the tablets, as they have a bitter taste and the coating is designed for controlled release.
• Oral Solution: Use a calibrated measuring device (oral syringe or medicine cup) provided by the pharmacy. Do not use a household teaspoon, as it is not accurate for medication dosing.
• Storage: Store at room temperature (20°C to 25°C / 68°F to 77°F). Keep the bottle tightly closed and out of reach of children.

If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose (within 4-6 hours), skip the missed dose and return to your regular schedule. Do not double the dose to make up for a missed one, as this significantly increases the risk of side effects like severe dizziness or fainting.

Signs of a Lacosamide overdose may include severe dizziness, nausea, vomiting, seizures, or cardiac conduction problems (slowed heart rate). In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately. There is no specific antidote for Lacosamide; treatment is supportive and may include gastric lavage or cardiac monitoring.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as sudden discontinuation can trigger breakthrough seizures.

Most side effects of Lacosamide are dose-related and occur most frequently during the titration phase (when the dose is being increased).

• Dizziness: This is the most frequently reported side effect. It may feel like a spinning sensation (vertigo) or general lightheadedness. It typically occurs shortly after taking a dose and may diminish as the body adjusts to the medication.
• Headache: Patients often report mild to moderate tension-type headaches during the first few weeks of treatment.
• Nausea: This can often be mitigated by taking the medication with food.
• Diplopia (Double Vision): Blurred or double vision is common, particularly at higher doses. Patients should avoid driving if they experience visual disturbances.

Lacosamide is a potent neurological medication that requires careful monitoring. Patients must be aware that this drug can impair mental and physical abilities. It is vital to maintain open communication with your neurology team throughout the duration of treatment.

There are no specific FDA black box warnings for Lacosamide as of 2026. However, it carries significant warnings regarding cardiac health and psychiatric well-being that must be taken as seriously as a black box warning.

Cardiac Risks (QT and PR Interval)

Lacosamide has been shown to cause dose-dependent prolongations in the PR interval on an electrocardiogram (EKG). This can lead to various degrees of 'heart block' (AV block). Patients with known conduction problems (such as marked first-degree AV block, second-degree or higher AV block without a pacemaker) or severe cardiac disease (such as myocardial infarction or heart failure) are at a higher risk. Your doctor may perform an EKG before starting the drug and after you reach your steady-state dose.

While there are few absolute contraindications for Lacosamide, it should not be used with other drugs that cause severe PR interval prolongation in patients who already have underlying heart block. There are no drugs that are strictly 'forbidden' in all patients, but combinations with certain Class I antiarrhythmics (like quinidine or procainamide) are generally avoided due to the high risk of cardiac arrest.

• PR Interval Prolonging Medications: Drugs such as beta-blockers (e.g., atenolol, metoprolol), calcium channel blockers (e.g., verapamil, diltiazem), and digoxin can have an additive effect with Lacosamide on the heart's electrical system. This can lead to dangerously slow heart rates.
• Strong CYP2C19 and CYP3A4 Inducers: Medications like Rifampin, St. John’s Wort, Phenobarbital, and Carbamazepine can increase the metabolism of Lacosamide, potentially lowering its concentration in the blood and reducing its ability to prevent seizures.

Lacosamide is strictly contraindicated in the following situations:

1. 1Hypersensitivity to Lacosamide: Patients who have had a previous severe allergic reaction (such as anaphylaxis or angioedema) to Lacosamide or any of the inactive ingredients in the tablets or oral solution must not take this medication.
2. 2Severe Heart Block: It is contraindicated in patients with known second- or third-degree atrioventricular (AV) block, unless the patient has a functioning artificial pacemaker. The drug's effect on the PR interval can worsen these conditions, potentially leading to complete heart block or asystole (the heart stopping).

Relative contraindications require a careful risk-benefit analysis by a medical professional:

Lacosamide is classified as a pregnancy risk by the FDA. Data on its use in pregnant women are limited. Animal studies have shown developmental toxicity (including increased embryofetal mortality and decreased fetal body weights) at doses similar to or lower than the maximum recommended human dose.

• Pregnancy Registry: Women who become pregnant while taking Lacosamide are encouraged to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. This registry collects data on the safety of anticonvulsants during pregnancy.
• Clinical Considerations: Seizure control is vital during pregnancy, as uncontrolled seizures can pose a risk to both the mother and the fetus. The decision to continue Lacosamide should involve a specialist (neurologist and high-risk obstetrician).

Studies in animals and limited human data indicate that Lacosamide is excreted into breast milk. The effects on the nursing infant are not fully known, but there is a theoretical risk of sedation or changes in feeding patterns. Healthcare providers must weigh the benefits of breastfeeding against the potential risks to the infant. If breastfeeding while taking Lacosamide, monitor the infant for excess sleepiness or poor weight gain.

Lacosamide is a functionalized amino acid that exerts its anticonvulsant effect through a highly specific modulation of voltage-gated sodium channels. Unlike other sodium channel blockers that bind to the 'fast inactivation' state of the channel, Lacosamide selectively enhances slow inactivation.

Voltage-gated sodium channels are responsible for the generation and propagation of action potentials in neurons. By increasing the proportion of channels in the slow-inactivated state, Lacosamide reduces the availability of these channels to open in response to rapid, repetitive stimuli. This effectively 'dampens' the hyperexcitability of neurons in the seizure focus without significantly affecting normal, low-frequency neuronal activity. This specificity is believed to contribute to its efficacy in focal epilepsy.

Lacosamide shows a clear dose-response relationship regarding its plasma concentration and its ability to reduce seizure frequency. The onset of effect can be seen within hours of the first dose (especially if a loading dose is used), but steady-state concentrations—and thus full therapeutic effect—are typically reached after 3 days of consistent dosing. There is no evidence of the development of tolerance to its anticonvulsant effects over time.